Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 3/2013

01-06-2013 | Correspondence

Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison

Authors: Carlos I. Alatorre, Virginia Haynes, Douglas Faries, Himanshu Upadhyaya, Douglas Kelsey

Published in: Applied Health Economics and Health Policy | Issue 3/2013

Login to get access

Excerpt

In the November 1, 2012 issue of the Applied Health Economics and Health Policy journal, Erder et al. [1] discussed the cost effectiveness of guanfacine extended-release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/hyperactivity disorder using a matching-adjusted indirect comparison. We would like to alert you that, after careful review of this article, we noticed a couple of data inaccuracies in the reporting of publicly available ATX data that met the inclusion criteria for trial selection for the indirect comparison. …
Literature
1.
Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy. 2012;10(6):381–95.PubMedCrossRef
2.
Michelson D, Faries D, Wernicke J, Kelsey D, Atomoxetine ADHD Study Group, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.PubMedCrossRef
Metadata
Title
Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison
Authors
Carlos I. Alatorre
Virginia Haynes
Douglas Faries
Himanshu Upadhyaya
Douglas Kelsey
Publication date
01-06-2013
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 3/2013
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-013-0024-2

Other articles of this Issue 3/2013

Applied Health Economics and Health Policy 3/2013 Go to the issue

Original Research Article

A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use

Original Research Article

Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective

Original Research Article

A Pilot Discrete Choice Experiment to Explore Preferences for EQ-5D-5L Health States

Original Research Article

Economic Burden of Non-Cystic Fibrosis Bronchiectasis in the First Year after Diagnosis from A US Health Plan Perspective

Erratum

Erratum to: Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

Original Research Article

Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome